News articles about Aimmune Therapeutics (NASDAQ:AIMT) have trended somewhat negative on Tuesday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aimmune Therapeutics earned a news impact score of -0.12 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the stock’s share price in the immediate future.
Shares of Aimmune Therapeutics (AIMT) traded down 2.42% during midday trading on Tuesday, hitting $20.54. 135,890 shares of the company were exchanged. Aimmune Therapeutics has a one year low of $12.34 and a one year high of $27.31. The stock’s 50-day moving average is $20.77 and its 200-day moving average is $19.92. The stock’s market cap is $1.03 billion.
Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings data on Monday, May 8th. The biotechnology company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.05. Equities research analysts anticipate that Aimmune Therapeutics will post ($2.66) EPS for the current year.
Several research firms recently weighed in on AIMT. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “sell” rating to a “buy” rating and set a $21.00 target price on the stock in a report on Tuesday, May 16th. Wedbush restated an “outperform” rating and set a $42.00 target price on shares of Aimmune Therapeutics in a report on Monday, July 24th. ValuEngine upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 13th. Finally, Piper Jaffray Companies set a $38.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $33.00.
In other news, insider Stephen George Dilly sold 49,400 shares of the firm’s stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $20.21, for a total transaction of $998,374.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Susan E. Barrowcliffe sold 6,110 shares of the stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $22.00, for a total transaction of $134,420.00. Following the sale, the insider now owns 960 shares of the company’s stock, valued at approximately $21,120. The disclosure for this sale can be found here. Insiders have sold a total of 189,070 shares of company stock valued at $3,954,182 over the last ninety days. 24.56% of the stock is owned by insiders.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with our FREE daily email newsletter.